Corie Lok is Xconomy's Special Projects Editor. Before joining Xconomy in 2017, she was at Nature for 12 years, first as an editor with the Careers section, then as a senior editor who launched Nature Network (a blogging and social networking website), and finally as an editor and features writer on Nature’s news team.
She earned a master’s degree in science journalism from Boston University and was a producer on the science and health beat for two national radio shows at the Canadian Broadcasting Corporation (CBC) in Toronto. She then spent two years covering emerging technologies with MIT Technology Review before arriving at Nature.
Corie is based in Boston and loves reading stories to her young son and playing the obscure but exciting winter sport of curling.
Biotech party organizers don’t seem to have learned the lesson from two years ago, when an infamous life science party in San Francisco with hired models in short dresses sparked outrage... Read more »
In an article published yesterday, National Institutes of Health leaders detailed how the NIH will spend the $500 million it got from Congress earlier this year to fight the opioid addiction... Read more »
Since President Trump announced his plan last month to lower prescription drug prices, a lot of rumors have been flying around that cuts are coming from certain companies, such as those... Read more »
The life science industry is undergoing unprecedented change, with the recent commercialization of groundbreaking new treatments like gene therapy, the growing adoption of digital technologies, and increasing backlash against high drug... Read more »
At this rate, 2018 could be a record-breaking year for biotech IPOs. Two more Boston-area companies filed their IPO plans late last week. Neon Therapeutics is developing personalized cancer vaccines, one... Read more »
The story of how genes are regulated has gotten a whole lot more complicated in recent years. Scientists, using ever-improving sequencing technologies, are discovering the many ways the cell can turn... Read more »
With biotech flush with venture capital funding, it seems that every hot new area of biology research now comes with its own startup. The latest is Celsius Therapeutics, and the new... Read more »
Ironwood Pharmaceuticals (NASDAQ: IRWD) is making the unusual move of splitting up into two separate, publicly traded companies. One, which will keep the Ironwood name, will focus on selling... Read more »
[Updated 4/28/18, 11:30 a.m. See below.] With all the buzz this week about the new CRISPR diagnostic startup from the University of California, Berkeley lab of Jennifer Doudna, perhaps... Read more »
As new technologies give drug developers greater insight into protein biology, more biotech and pharma companies are now emboldened to pursue what have long been dismissed as undruggable targets—the 75-85 percent... Read more »
After months of meetings and Congressional hearings on the unrelenting opioid addiction crisis, Congress has finally responded, with 25 bills that aim to attack the problem from all sides. The House... Read more »
For 20 years, Deborah Long (pictured) has been relying on powerful drugs to keep her multiple sclerosis in check. Her out-of-pocket costs were pretty reasonable until two years ago, she says,... Read more »
Skin-drug company Dermira today announced that two pivotal Phase 3 trials testing its experimental acne drug, olumacostat glasaretil, failed to meet their main goals. The company said that based on those... Read more »
CRISPR pioneers and competitors Jennifer Doudna and Feng Zhang are once again locked in a CRISPR race, this time to show how CRISPR—the technology best known for its gene-editing prowess—can also... Read more »
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.